%0 Journal Article %A Sattva S Neelapu %A Sherry Adkins %A Stephen M Ansell %A Joshua Brody %A Mitchell S Cairo %A Jonathan W Friedberg %A Justin P Kline %A Ronald Levy %A David L Porter %A Koen van Besien %A Michael Werner %A Michael R Bishop %T Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma %D 2020 %R 10.1136/jitc-2020-001235 %J Journal for ImmunoTherapy of Cancer %P e001235 %V 8 %N 2 %X The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma. %U https://jitc.bmj.com/content/jitc/8/2/e001235.full.pdf